CPIX

This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Successfully closed the strategic transaction with Apotex Health, receiving $100 million in cash at closing with an additional $11 million due over the next 12 months and a potential $10 million milestone payment. Shareholders overwhelmingly approved the transaction with over 99% voting in favor, reflecting strong confidence in the company's new strategic direction. Declared and funded a special dividend of $1.50 per share, returning capital to shareholders while retaining sufficient funds for long-term operations. Strengthened financial position with projected cash reserves of over $50 million available for unexpected expenses and special opportunities, and cash runway of over five years. Advanced clinical pipeline with multiple milestones expected in 2026, including top-line results for systemic sclerosis, interim efficacy for IPF, and continued FDA discussions for DMD. Positive phase two results from the Vanderbilt collaboration on cancer metastasis prevention, showing fewer metastatic recurrences and deaths in the treatment arm. FDA granted fast-track designation for ifetroban in DMD, along with orphan drug and rare pediatric disease designations, supporting a clear regulatory pathway. Retired the bank line of credit, reducing total liabilities and simplifying the balance sheet. Taxes on the transaction are estimated to be less than $1 million due to tax loss carryforwards and R&D tax credits, maximizing net proceeds. Company is now focused on innovation with a strong safety profile for ifetroban, administered to approximately 1,400 subjects across multiple studies. Reported an operating loss of $3.1 million and a net loss of $4.1 million for the second quarter. Cash and cash equivalents were only approximately $4 million as of June 30, 2026, before the transaction proceeds were received. The company is transitioning away from its commercial portfolio, which previously generated significant revenue and expenses (nearly $32 million in 2025), leading to a complete change in revenue streams. Future operating results will primarily reflect investment in clinical development, with no guarantee of successful product approvals or commercialization. The company's success now hinges on the advancement of its clinical pipeline, which carries inherent risks of trial failures, regulatory hurdles, and delays. The special dividend of $22 million reduces the capital available for other strategic opportunities, though management believes it is balanced with long-term funding needs. The company faces the risk of not achieving key clinical milestones, such as top-line results for systemic sclerosis or interim efficacy for IPF, which could negatively impact investor sentiment. The strategic transaction involves integration risks and the need to manage a new operational structure as a development-focused company. The company's financial statements will differ meaningfully from prior periods, potentially causing confusion among investors and requiring a new evaluation framework. There is no guarantee that any of the development programs will receive FDA approval, and even if one does, it may not generate significant value as anticipated. Warning! GuruFocus has detected 5 Warning Sign with CPIX. Is CPIX fairly valued? Test your thesis with our free DCF calculator. Q: What are the key financial details and strategic implications of the recently completed transaction with Apotex Health?A: AJ Kazimi, CEO, confirmed that the strategic transaction with Apotex Health closed on July 1, 2026, after receiving over 99% shareholder approval. Under the terms, Apotex acquired Cumberland's FDA-approved commercial brands and related U.S. organizations. Cumberland received $100 million in cash at closing, with an additional $11 million due for inventory and transition payments, plus a potential $10 million milestone payment. This transaction transforms Cumberland into an innovation-focused biopharmaceutical company, providing the financial strength to accelerate its clinical pipeline, particularly the ifetroban programs. Q: How will the proceeds from the Apotex transaction be utilized, and what is the company's updated financial outlook?A: John Hamm, CFO, detailed that the net proceeds from the transaction are estimated at $108 million, including the $100 million upfront and $11 million in additional funds, with taxes estimated at less than $1 million due to tax loss carryforwards and R&D credits. The board declared a special dividend of $1.50 per share, totaling $22 million. The remaining cash is projected to fund operations for over five years, with additional reserves of over $50 million available for unexpected expenses or special opportunities. The company's primary financial priorities are funding development programs, maintaining a strong balance sheet, and preserving financial flexibility. Q: What is the current status and regulatory progress of the Duchenne Muscular Dystrophy (DMD) program?A: Todd Anthony, VP of Organizational Development, reported that the Phase II FIGHT-DMD trial demonstrated positive top-line results with encouraging safety and biomarker findings. The FDA granted fast-track designation for ifetroban in DMD earlier this year, adding to existing orphan drug and rare pediatric disease designations. New biomarker data presented at the Parent Project Muscular Dystrophy Annual Conference in Q2 provided additional evidence that the therapy can help preserve cardiac function. Discussions with the FDA regarding the regulatory pathway are ongoing, with another meeting scheduled for the fall. Q: What are the latest developments in the systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF) programs?A: Todd Anthony confirmed that patient enrollment in the systemic sclerosis Phase II study has been completed, with top-line results anticipated this year. For the IPF program, an interim safety analysis of the first cohort of patients completing 12 weeks of treatment found no new safety signals, allowing patient enrollment to continue. The company expects to announce interim efficacy results as the next milestone for the IPF study. Q: What were the results of the oncology collaboration with Vanderbilt Health, and what are the next steps?A: Todd Anthony announced positive results from the Phase II clinical trial evaluating ifetroban for the prevention of cancer metastasis in patients with high-risk solid tumors. The study met its primary endpoint, demonstrating that ifetroban was safe and well tolerated. Encouraging efficacy signals were observed, including fewer patients experiencing metastatic recurrence and fewer metastasis-related deaths in the treatment arm compared to placebo. The company is working with Vanderbilt to determine the next steps for this oncology program. Q: What were the company's financial results for the second quarter of 2026?A: John Hamm reported that the company reorganized its income statement to classify revenue and expenses associated with the Apotex transaction as discontinued operations. The ongoing investment in R&D resulted in an operating loss of $3.1 million for the quarter, with a net loss of $4.1 million including discontinued operations. As of June 30, 2026, total assets were $63 million, including approximately $4 million in cash. The company retired its bank line of credit with a $5.2 million payment, reducing total liabilities to $46 million and resulting in shareholders' equity of approximately $17 million. Q: How will the company's financial statements change following the divestiture of its commercial brands?A: John Hamm explained that Cumberland will no longer record revenue from the commercial brands or related expenses, including cost of goods, sales, and marketing, which totaled nearly $32 million in 2025. Future operating results will primarily reflect investment in clinical development and regulatory activities, supported by manufacturing and corporate administrative expenses, along with any future milestone or collaboration payments. This simplifies the operating structure and strengthens the balance sheet as the company transitions to a development-focused biopharmaceutical entity. Q: What are the key clinical milestones expected for the remainder of 2026?A: AJ Kazimi outlined several anticipated milestones: continued FDA discussions for the DMD program to define the regulatory pathway; final analysis and top-line results for the systemic sclerosis study; interim efficacy findings for the IPF study; and evaluation of next steps for the oncology collaboration with Vanderbilt. These milestones represent opportunities to advance development programs and build value for patients and shareholders. Q: What is the significance of the ifetroban clinical programs, and how many subjects have been treated?A: Todd Anthony highlighted that ifetroban, Cumberland's first new chemical entity, is a potent and selective thromboxane receptor antagonist that has been administered to approximately 1,400 subjects across multiple clinical studies, demonstrating a strong safety profile. The compound is being evaluated across several advanced clinical programs targeting diseases with significant unmet medical needs, including DMD, systemic sclerosis, IPF, and cancer metastasis prevention. Q: What role does Cumberland Emerging Technologies (CET) play in the company's strategy?A: Todd Anthony noted that CET remains an important strategic asset, playing a valuable role in identifying, supporting, and advancing innovative biomedical technologies from leading research institutions. Through CET, Cumberland collaborates with academic investigators, healthcare institutions, and emerging life sciences companies to translate promising scientific discoveries into potential therapeutic products, complementing internal development efforts and expanding access to innovative technologies for future growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better. Cumberland completed the sale of its branded U.S. commercial portfolio to Apotex for $100 million upfront, with up to $21 million in additional inventory, transition and milestone payments. The company also returned approximately $22 million to shareholders through a $1.50-per-share special dividend. The transaction shifts Cumberland’s focus to an innovation-driven biopharmaceutical model centered on ifetroban. The company expects its remaining cash to fund operations for more than five years while advancing programs in Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis. Key 2026 catalysts include systemic sclerosis top-line results, interim efficacy data from the pulmonary fibrosis study and further FDA discussions on Duchenne muscular dystrophy. Cumberland also reported encouraging early efficacy signals from an ifetroban oncology collaboration with Vanderbilt. Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health. The transaction, which closed July 1, delivered $100 million in cash at closing. Cumberland said it also expects to receive $11 million for inventory and transition payments over the next 12 months, as well as a potential $10 million milestone payment. The company estimated net proceeds from the transaction of approximately $108 million, after taxes of less than $1 million. → SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Chief Executive Officer A.J. Kazimi called the Apotex agreement a defining milestone for the company, saying it strengthens Cumberland’s financial position and allows management to concentrate on advancing its clinical pipeline centered on the drug candidate ifetroban. “With the divestiture of our commercial brands, our strategy and focus now centers on advancing our ifetroban clinical programs,” Kazimi said. → Financials Hit Record Highs as the AI Trade Unravels—Can They Keep Leading? Cumberland shareholders approved the Apotex transaction in June, with more than 99% of voting shareholders supporting the agreement, according to Kazimi. The company subsequently funded a special dividend of $1.50 per share, totaling approximately $22 million based on roughly 15 million shares outstanding. Chief Financial Officer John Hamm said the company believes its remaining cash can fund operations for more than five years while it invests in clinical development. Cumberland also estimates that more than $50 million in additional cash reserves will remain available for unexpected expenses and potential strategic opportunities. → Why Rare Earth Processing Could Be the Real 2027 Opportunity As of June 30, Cumberland reported total assets of $63 million, including about $4 million in cash and cash equivalents. The company retired its bank line of credit with a $5.2 million payment at the end of the quarter, reducing total liabilities to $46 million and leaving shareholder equity of approximately $17 million. Hamm said the company’s financial reporting will change materially in future periods because revenue and expenses related to the commercial brands will no longer be recorded after the transaction. During the second quarter, Cumberland classified the revenue and expenses associated with the Apotex transaction as discontinued operations. Including discontinued operations, Cumberland’s net loss was $4.1 million for the quarter. Hamm noted that expenses related to the commercial business, including cost of goods sold, sales and marketing, totaled nearly $32 million in 2025. Cumberland’s development strategy now centers on ifetroban, a thromboxane receptor antagonist that has been administered to approximately 1,400 subjects in multiple clinical studies, according to Todd Anthony, vice president of organizational development. The company is evaluating ifetroban in several advanced clinical programs addressing rare and serious diseases: Duchenne muscular dystrophy: Cumberland is developing ifetroban to preserve cardiac function in patients with Duchenne muscular dystrophy-associated cardiomyopathy. The company previously reported positive top-line Phase II results from its FIGHT DMD study, including safety and biomarker findings. The FDA granted Fast Track designation earlier this year, supplementing prior Orphan Drug and Rare Pediatric Disease designations. Cumberland plans to continue regulatory discussions with the FDA, with another meeting scheduled for the fall. Systemic sclerosis: Enrollment has been completed in the company’s Phase II study in patients with systemic sclerosis, a rare autoimmune disease involving progressive fibrosis and vascular dysfunction. Cumberland said it is evaluating the data and expects top-line results this year. Idiopathic pulmonary fibrosis: An independent committee reviewing the first cohort of patients completing 12 weeks of treatment found no new safety signals and recommended no changes to the study’s conduct. Enrollment is continuing, and Cumberland expects interim efficacy results to be the next milestone. During the quarter, new biomarker findings from the FIGHT DMD study were presented at the Parent Project Muscular Dystrophy Annual Conference. Anthony said the findings provided additional evidence that the therapy may help preserve cardiac function in the studied patient population. Cumberland also highlighted its collaboration with Vanderbilt Health to assess ifetroban in preventing cancer metastasis among patients with high-risk solid tumors. The partners announced positive Phase II results during the second quarter. The study met its primary endpoint by demonstrating that ifetroban was safe and well tolerated, Anthony said. The trial also produced what the company described as encouraging efficacy signals, including fewer patients experiencing metastatic recurrence and fewer deaths related to metastasis in the ifetroban treatment arm compared with placebo. Cumberland said it will work with Vanderbilt to determine next steps for the oncology program. Management said the company expects several clinical milestones during the remainder of 2026, including top-line systemic sclerosis data, interim efficacy findings from the idiopathic pulmonary fibrosis study and continued discussions with the FDA on the Duchenne muscular dystrophy regulatory pathway. “Going forward, investors should increasingly evaluate Cumberland based on the advancement of our clinical pipeline, execution against key development milestones, and the management of the company’s capital resources,” Hamm said. Kazimi said Cumberland also intends to continue identifying potential biomedical opportunities through Cumberland Emerging Technologies, which collaborates with academic institutions, healthcare organizations and life sciences companies to help advance emerging technologies. Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint. The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Cumberland Pharmaceuticals Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health. During the second quarter, Cumberland completed a transaction with Apotex Health, the largest Canadian pharmaceutical company, to integrate their branded business. Under the terms of the agreement, Apotex acquired Cumberland's portfolio of FDA-approved brands and related commercial organization for $100 million in cash at closing, plus an additional $11 million in funding for inventory and transition services. Following the transaction, Cumberland will transition into a development-stage biopharmaceutical organization focused on advancing differentiated medicines for rare diseases and other areas of significant unmet medical need. Cumberland returned capital to shareholders through a special cash dividend while retaining sufficient resources to fund its long-term operations, advance its development pipeline and pursue additional strategic opportunities. Cumberland retains its development pipeline of late stage candidates, including four Phase 2 clinical programs, as well as its majority ownership in Cumberland Emerging Technologies. "The second quarter marked a defining milestone for Cumberland," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "With the successful completion of our Strategic Transaction, we have unlocked substantial value for our shareholders, while positioning Cumberland for its next phase as an innovation-focused biopharmaceutical company. We have strengthened our balance sheet, returned capital to shareholders through a special dividend and remain well-capitalized to advance our pipeline of differentiated product candidates designed to address significant unmet medical needs." RECENT COMPANY DEVELOPMENTS INCLUDE: Completion of Strategic Transaction with Apotex On July 1, 2026, Cumberland announced the closing of its agreement with Apotex to integrate the U.S. branded businesses. Under the terms of the agreement, Apotex acquired Cumberland's portfolio of FDA-approved brands for $100 million in cash consideration, plus an additional $11 million in funding for inventory and transition services. The transaction was unanimously approved by Cumberland's Board of Directors, which was followed by approval from Cumberland's shareholders, with over 99% of the voting shares in favor of the transaction. Cumberland has retained its development programs, as well as its majority ownership in Cumberland Emerging Technologies. This transaction positions Cumberland to operate as an innovation-focused development-stage biopharmaceutical organization. Board Declares a Special Dividend Cumberland's Board of Directors authorized and declared a special cash dividend of $1.50 per share of the company's common stock. The dividend was paid on July 31, 2026, to the shareholders of record as of July 23, 2026. Following the closing of the transaction with Apotex, an analysis by Cumberland's tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland's Board assessed its future cash needs and evaluated possible alternatives for the excess capital. The Board of Directors determined that after the payout of the special dividend, Cumberland will still have significant liquidity and financial flexibility to fund its long-term product development efforts, with additional reserves available to address any new opportunities. Updated DMD Results Shared at PPMD Conference In June 2026, Cumberland presented updated results from its Phase 2 FIGHT DMD clinical trial evaluating ifetroban in patients with Duchenne muscular dystrophy-associated cardiomyopathy at the annual Parent Project Muscular Dystrophy (PPMD) Conference. The updated data included new blood biomarker findings directionally consistent with heart muscle protection, with increases in markers of cardiac protection and repair and reductions in markers of heart muscle injury and cell damage with ifetroban treatment. These biomarker results reinforce the previously reported improvements in cardiac function, consistent with ifetroban's ability to slow the progression of DMD-related heart disease. Together, the findings strengthen the case for developing ifetroban as a therapy targeting cardiomyopathy, the leading cause of death in patients with DMD. Positive Results in Cancer Metastasis Prevention In collaboration with Vanderbilt Health, Cumberland announced results from a randomized, placebo-controlled Phase 2 study evaluating ifetroban as a potential therapy to inhibit cancer metastasis in patients with Stage I to III malignant solid tumors at high risk of metastatic recurrence. The study met its primary objective of assessing safety and feasibility. Ifetroban was found to be safe and well-tolerated, and no safety signals were identified in markers of blood clotting function. Although intentionally not powered for efficacy, the study also compared the percentage of patients with distant metastatic recurrence 12 months after completion of therapy in both groups (10 placebo-treated and 18 ifetroban-treated participants) as a prespecified secondary endpoint. Metastatic recurrence occurred in 3 of 18 patients (17%) receiving ifetroban, compared with 5 of 10 patients (50%) receiving placebo, a difference that did not reach statistical significance (odds ratio 0.21; p=0.09). There were no deaths from distant metastatic disease among patients receiving ifetroban, compared with 3 of 10 patients (30%) receiving placebo (p=0.037). The findings support the continued clinical development of ifetroban as a potential approach to inhibiting the metastatic process, an area of significant unmet medical need. FINANCIAL RESULTS: Net Revenue: During the second quarter of 2026, Cumberland reorganized its income statement to classify the revenues and expenses associated with the Apotex transaction as discontinued operations. The ongoing investment in research and development, supported by the remaining general and administrative expenses, resulted in a loss from continuing operations of $3.1 million for the quarter. With the addition of discontinued operations, the net loss for the quarter was $4.1 million. Balance Sheet: At June 30, 2026, Cumberland had approximately $63 million in total assets, including $4 million in cash and cash equivalents. Liabilities totaled $46 million and total shareholders' equity was $17 million on June 30, 2026. Cumberland retired its bank line of credit through a payment of $5.2 million at the end of the second quarter. EARNINGS REPORT CALL: A conference call will be held today, August 4, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results. The link to register is https://register-conf.media-server.com/register/BI2da176d5d0dd4778a44db3d4af6e7b39. Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting: https://edge.media-server.com/mmc/p/xokd879m. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit www.cumberlandpharma.com. FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. - MORE - The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others. Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release. Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization of intangible and right-of-use assets, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance. The Company defines these supplemental financial measures as follows: Adjusted Earnings (loss): Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. (a) Represents the share-based compensation of Cumberland. (b) Represents the straight line reduction in carrying value of right-of-use assets. Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-company-update--q2-2026-financial-results-302842997.html

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida. The presentation highlighted key updates to the primary findings in the FIGHT DMD trial, reinforcing ifetroban's potential to address the leading cause of death in patients with DMD. The presentation was delivered by Chet R. Villa, MD, a pediatric cardiologist at Cincinnati Children's Hospital Medical Center and one of the leaders of the muscular dystrophy committee in Advanced Cardiac Therapies Improving Outcomes Network (ACTION) as part of the conference program. "Cardiomyopathy is the leading cause of mortality in patients with Duchenne muscular dystrophy, and there are currently no approved treatments that specifically target the underlying cardiac disease," said Dr. Villa. "As a site investigator on the FIGHT DMD trial, I have seen the importance of identifying therapies that protect cardiac function in these young patients. The updated findings being presented today include the reduction in markers of heart muscle injury alongside the previously reported improvement in left ventricular ejection fraction. These demonstrate that ifetroban slows ongoing heart damage in patients with DMD compared to natural history studies, addressing a critical unmet need, and sharing these results with the PPMD community is particularly meaningful." The complete set of slides presented at the PPMD conference is now available on Cumberland's website. The 12-month Phase 2 FIGHT DMD trial (NCT03340675) previously demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group composed of placebo-treated patients combined with propensity score-matched natural history patients. The study findings also included reductions in cardiac damage markers (NT-proBNP and cardiac troponin I) in the high-dose group. All patients who completed the 12-month study opted to continue in the open-label extension. New findings from the Phase 2 FIGHT DMD trial, supported by long-term safety data from the ongoing open-label extension, further characterize the cardioprotective effect exerted by ifetroban in DMD cardiomyopathy. Through 36 months of treatment across both the Phase 2 trial and the open-label extension, ifetroban maintained a favorable safety profile in DMD patients with no treatment-related serious adverse events or new safety concerns. Evaluation of novel blood biomarkers identified a 30% reduction in MYL3 and a 50% reduction in MYOD1 (circulating markers of heart muscle and cell damage), alongside a 2.4-fold increase in FGF16 and a 2.1-fold increase in TSPAN7 (cardioprotective and tissue repair proteins) with ifetroban treatment compared with placebo. These confirmatory findings further support the potential therapeutic mechanisms for ifetroban in DMD cardiomyopathy. "The results being shared at this year's PPMD conference continue to strengthen our confidence in ifetroban's potential to address the cardiomyopathy that affects all patients with Duchenne muscular dystrophy. The improvement in cardiac function we observed in the 12-month study is supported by additional biological evidence that ifetroban can help protect the heart from ongoing injury," said A.J. Kazimi, Cumberland CEO. Pat Furlong, founding president and chief executive officer of Parent Project Muscular Dystrophy, said, "For more than three decades, we have worked to ensure that cardiac care receives the attention it deserves in Duchenne muscular dystrophy. Cardiomyopathy affects nearly every patient with DMD, and the absence of treatments designed specifically for this aspect of the disease has been a critical gap in care for the families we serve. The updated results from the FIGHT DMD trial being shared at this year's conference are encouraging and bring families closer to having a therapy that targets the underlying cardiac disease. We thank Cumberland for its continued investment in this work, and we recognize the contributions of the investigators and the families who took part in the trial." Ifetroban is a once-daily oral medication that works by blocking the thromboxane receptor, which plays a key role in inflammation and fibrosis. The drug has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the indication of cardiomyopathy associated with DMD. There is currently no approved treatment specifically targeting DMD heart disease, highlighting the critical unmet medical need in this patient population where cardiac complications are universal and represent the leading cause of death. Cumberland has secured a growing portfolio of patents protecting the product for this DMD heart disease indication. Next steps include the completion of long-term treatment analyses, and the conduct of additional supportive studies. More information regarding the FIGHT DMD Trial is available at www.fightdmdtrial.com About Duchenne Muscular Dystrophy (DMD) DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure. While current treatments can help manage some DMD symptoms, there are no approved therapies specifically targeting DMD-related heart disease, highlighting a critical unmet medical need. About Parent Project Muscular Dystrophy (PPMD) Parent Project Muscular Dystrophy is a grassroots, parent-led advocacy group with the mission to end DMD. Since its founding in 1994, PPMD has helped to accelerate treatments through research funding, to provide access to optimal DMD care for families, and to affect legislation through advocacy to improve the lives of children with DMD and their families. PPMD also hosts an annual conference which is the largest, most comprehensive, annual international conference focused entirely on DMD. This conference connects families across the world to share their stories and serves as a forum to highlight the progress in ending DMD. About FIGHT DMD FIGHT DMD is a community-based organization founded by Terry and Sonya Marlin with the mission of advancing research into DMD heart disease. The organization has provided crucial early-stage funding for multiple research projects focused on understanding and treating cardiac complications in DMD patients. Their support has been instrumental in advancing preclinical research that led to FDA grant funding for clinical trials, demonstrating the power of family-driven advocacy in catalyzing medical innovation. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis. For more information, please visit www.cumberlandpharma.com. Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-shares-updated-fight-dmd-trial-results-at-the-parent-project-muscular-dystrophy-annual-conference-302811988.html

Apotex transaction: Cumberland agreed to sell its U.S. portfolio to Apotex for $100 million in cash (plus about $9 million for inventory, transitional fees and a potential sales milestone) subject to shareholder approval, and plans to pivot to a development-focused company after closing. Q1 financials: Revenue was $9.1 million with a net loss of about $3.3 million (adjusted loss $1.9 million, $0.13 per share); the company generated positive operating cash flow of $387,000 and held $11 million in cash as of March 31, 2026, and said it is no longer targeting double-digit revenue growth for the year given the pending deal. Pipeline progress: Ifetroban received FDA Fast Track designation for Duchenne muscular dystrophy (in addition to prior Orphan and Rare Pediatric designations), and multiple Phase II programs (scleroderma, idiopathic pulmonary fibrosis) are advancing with enrollment and interim safety data reported. Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better. Cumberland Pharmaceuticals (NASDAQ:CPIX) executives highlighted a planned strategic transaction with Apotex, updates across several marketed brands, and progress in the company’s late-stage pipeline during the company’s first-quarter 2026 earnings call. Chief Executive Officer A.J. Kazimi said Cumberland has entered into an agreement with Apotex, which he described as “the largest Canadian-based pharmaceutical company,” to integrate the companies’ branded U.S. commercial businesses. Under the terms described on the call, Apotex will acquire Cumberland’s portfolio of marketed products for $100 million in cash, subject to shareholder approval. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Kazimi said Cumberland also expects to receive $9 million in payments for inventory, fees for transitional support services, and an additional milestone payment tied to future product sales. He characterized the agreement as “a significant event” that the company expects will “unlock substantial near-term value” for shareholders and potentially expand patient access to its brands through Apotex’s larger market presence. Both Kazimi and CFO John M. Hamm pointed to the transaction’s expected tax impact. Kazimi said the company estimates resulting income taxes will be “modest,” which he said would allow the net consideration to significantly strengthen Cumberland’s balance sheet. Hamm added that Cumberland has “over $53 million in tax net operating loss carryforwards” and that the assets involved in the transaction have a “tax basis of $30 million,” supporting the company’s view that taxes should be modest. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches After closing, Kazimi said Cumberland intends to pivot toward a development-focused strategy, concentrating on advancing its pipeline and positioning the company as an “innovation-driven organization, developing new medicines for the future.” Vice President of Organizational Development Todd M. Anthony reviewed key commercial updates for several products. Caldolor: Anthony said Cumberland received FDA approval in April for an expanded indication for Caldolor (intravenous ibuprofen) to include the management of post-operative pain. He said the label now includes use in “adult and pediatric patients ages three months and older for the treatment of pain and fever,” and that the expanded labeling broadens use in perioperative and acute care settings. He also said Cumberland resubmitted its application to the Centers for Medicare & Medicaid Services during the first quarter for Caldolor’s inclusion under the NOPAIN Act program, which is designed to support non-opioid pain management therapies. Sancuso: Anthony said Cumberland launched a new Sancuso website during the quarter aimed at providing healthcare professionals and patients with educational resources, clinical information, and expert insights related to chemotherapy-induced nausea and vomiting. Talicia: Anthony said Cumberland launched national sales promotion efforts in February for Talicia, citing its co-commercialization agreement with Talicia Holdings, Inc., which he noted is jointly owned. He said Cumberland assumed responsibility for U.S. distribution and sales promotion and leveraged its existing field sales division alongside supporting marketing initiatives to increase awareness among gastroenterologists and other prescribers. Vaprisol: Anthony said the FDA reinstated approval status for the manufacturing facility where Cumberland transferred Vaprisol manufacturing, enabling the company to submit to manufacture Vaprisol at the site. He said Cumberland expects the brand’s relaunch this year once manufacturing submissions and commercial supply arrangements are completed. → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries Kazimi also referenced operational milestones early in 2026, including “the first shipment of Vibativ to China” and “FDA clearance of the manufacturing facility which will enable the relaunch of Vaprisol.” Hamm reported that combined revenue from Cumberland’s FDA-approved brands was $9.1 million in the first quarter. He said this represented a 5% increase after removing a one-time $3 million milestone payment recorded in the prior year associated with the approval of Vibativ in China. Net revenue by product for the first quarter of 2026 was: Kristalose: $1.0 million Sancuso: $2.9 million Vibativ: $2.1 million Caldolor: $1.0 million Talicia: $1.9 million Total operating expenses were $12.3 million, resulting in a net loss of approximately $3.3 million for the quarter, Hamm said. On an adjusted basis that adds back non-cash expenses, Hamm reported an adjusted loss of $1.9 million, or $0.13 per share. Hamm said Cumberland generated positive cash flow from operations of $387,000 during the first quarter. He also noted that quarterly shipments can fluctuate due to customer buying patterns, the timing of international orders, and seasonality—adding that orders are typically strongest in the fourth quarter and lightest in the first quarter—so the company views performance “best evaluated on an annual basis.” As of March 31, 2026, Hamm said Cumberland had $71 million in total assets, including $11 million in cash and cash equivalents. Liabilities totaled $49.7 million, including $5 million on the credit facility, and shareholders’ equity was $21.6 million. Given the pending transaction, Hamm said Cumberland is “no longer targeting a goal of double-digit revenue growth for the year.” He also said expenses are expected to fall significantly after closing because Apotex would assume responsibility for sales, marketing, medical, manufacturing, and FDA fees associated with the brands. Hamm added that Cumberland does not expect a significant change in 2026 clinical spending levels as it advances product candidates in “advanced stages of development.” Kazimi outlined progress across Cumberland’s development pipeline, with a focus on ifetroban, a new chemical entity described on the call as “a potent and selective thromboxane receptor antagonist.” He said ifetroban has been dosed in nearly 1,400 subjects and has been “safe and well-tolerated” in those individuals. In Duchenne muscular dystrophy (DMD), Kazimi said Cumberland previously announced positive top-line results from a completed Phase II study and that, during the first quarter, the FDA granted Fast Track designation for ifetroban in DMD patients. He said the designation is intended to accelerate development and review and allows for more frequent FDA interaction, rolling submissions, and earlier guidance. He also noted the program previously received Orphan Drug and Rare Pediatric Disease designations. Kazimi said the company held an end-of-Phase II meeting with the FDA last fall and a follow-up meeting in the first quarter of 2026 to discuss DMD study results and determine the regulatory pathway and approval requirements. He said Cumberland is finalizing its plans and expects to announce additional results and timelines once those plans are completed. For systemic sclerosis (scleroderma), Kazimi said enrollment in the ifetroban study has been completed and top-line findings are expected “forthcoming.” In idiopathic pulmonary fibrosis, he said patient enrollment is “well underway” in U.S. centers for the Phase II Fighting Fibrosis trial. He also said an interim safety analysis of the first cohort completing 12 weeks of treatment found “no new safety signals,” and the independent committee recommended no changes to study conduct. Cumberland expects to announce interim efficacy results later this year, Kazimi said, and additional investigator-initiated pilot studies are also underway. The company attempted to open the call for questions, but the operator cited difficulties hearing questions and an echo on the line. Emily Kent of the Dalton Agency said Cumberland would take questions privately and asked participants to reach out to the company to schedule follow-up conversations. Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint. The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief. The article "Cumberland Pharmaceuticals Q1 Earnings Call Highlights" was originally published by MarketBeat.

Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders' equity. "We entered 2026 with strong momentum following an outstanding 2025, which featured double-digit revenue growth, the addition of a new product to our portfolio, new international approvals and breakthrough clinical study results," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "We have built on that momentum through our recently announced Strategic Transaction, which represents an important next step in our Company's evolution, enabling us to sharpen our focus on developing high-value product candidates, while unlocking significant value for our shareholders." RECENT COMPANY DEVELOPMENTS INCLUDE: Strategic Transaction Cumberland recently announced a Strategic Transaction with Apotex Inc., the largest Canadian-based pharmaceutical company, to integrate the branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire Cumberland's portfolio of FDA-approved brands for $100 million in cash consideration, subject to Cumberland shareholders' approval and certain other customary closing conditions. This transaction is designed to unlock value and sharpen Cumberland's focus on advancing its pipeline of differentiated product candidates designed to address unmet medical needs. The integration of Cumberland's products will create more critical mass to support patient care and expand product distribution. Following the closing of the transaction, Cumberland will retain its development programs, as well as its majority ownership in Cumberland Emerging Technologies. This positions Cumberland to operate with the profile of an innovative, development-stage biopharmaceutical organization devoted to new medicines for the future. Development Pipeline In addition to its portfolio of FDA-approved brands involved in the transaction with Apotex, Cumberland is developing ifetroban, a potent thromboxane antagonist, through a series of clinical programs designed to address unmet medical needs with significant market potential. Cumberland has announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Discussions with the FDA are underway regarding the study results and remaining requirements for approval. During the first quarter of 2026, the FDA granted Fast Track Designation for Cumberland's ifetroban candidate product for DMD patients. This designation is intended to accelerate the development and review of therapies that address serious conditions with unmet medical needs. Importantly, it allows for more frequent FDA interaction, rolling data submissions and earlier guidance throughout the approval process. The program previously received both Orphan Drug and Rare Pediatric Disease designations from the FDA. In addition, Cumberland has a Phase II clinical program evaluating its ifetroban product candidate in patients with Systemic Sclerosis ("SSc") or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs. Enrollment in the study is completed and the next milestone will be announcing its top-line study results. Cumberland's third development program involves the use of ifetroban in patients with Idiopathic Pulmonary Fibrosis ("IPF"), the most common form of progressive fibrosing interstitial lung disease. Enrollment in the study is well underway at medical centers across the U.S., with interim safety and interim efficacy results pending. FINANCIAL RESULTS: Net Revenue: For first quarter of 2026, the Company's net revenues of $9.1 million, which represented a 5% increase compared to the first quarter of 2025 after removing the $3 million milestone payment last year associated with the approval of Vibativﾮ in China. Cumberland's branded portfolio revenue included $1.0 million for Kristaloseﾮ, $2.9 million for Sancusoﾮ, $2.1 million for Vibativﾮ, $1.0 million for Caldolorﾮ and $1.9 million for Talicia.ﾮ Operating Expenses: Total operating expenses for the quarter were $12.3 million. Net Income (Loss): The net loss for the first quarter of 2026 was approximately $3.3 million. Adjusted Earnings (Loss): Adjusted loss for the quarter was $1.9 million, or $0.13 per share. Balance Sheet: At March 31, 2026, Cumberland had approximately $71.0 million in total assets, including $11.0 million in cash and cash equivalents. Liabilities totaled $49.7 million, including $5.2 million on the company's credit facility. Total shareholders' equity was $21.6 million on March 31, 2026. EARNINGS REPORT CALL: A conference call will be held today, May 5, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results. The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a. Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting: https://edge.media-server.com/mmc/p/rik67g7q. ABOUT CUMBERLAND PHARMACEUTICALS: Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadoteﾮ (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolorﾮ (ibuprofen) injection, for the treatment of pain and fever; Kristaloseﾮ (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancusoﾮ (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisolﾮ (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativﾮ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Taliciaﾮ (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com. About Acetadoteﾮ (acetylcysteine) Injection Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit www.acetadote.com. About Caldolorﾮ (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com. About Kristaloseﾮ (lactulose) Oral Solution Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com. About Sancusoﾮ (granisetron) Transdermal System Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com. About Vaprisolﾮ (conivaptan hydrochloride) Injection Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com. About Vibativﾮ (telavancin) for Injection Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com. About Taliciaﾮ Taliciaﾮ is an FDA approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer. Talicia is listed as a first line option in the 2024 ACG Guideline for the treatment of H. pylori and features three key advantages: 1) high eradication rates - >90% in confirmed adherent patients, 2) the simplicity of an all-in-one capsule, and 3) low resistance to the two antibiotics - amoxicillin and rifabutin. For more information, please visit www.talicia.com. FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others. Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release. Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization of intangible and right-of-use assets, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance. The Company defines these supplemental financial measures as follows: Adjusted Earnings (loss): Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. (a) Represents the share-based compensation of Cumberland. (b) Represents the straight line reduction in carrying value of right-of-use assets. Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-q1-2026-financial-results--company-update-302763267.html

Management announced a transformational agreement to sell its entire branded U.S. commercial portfolio to Apotex for $100 million in cash plus inventory and milestone payments, subject to shareholder approval. The strategic shift transitions Cumberland from a commercial-stage entity to an innovation-driven organization focused on advancing its robust pipeline of product candidates. Performance in Q1 2026 was characterized by a 5% revenue increase in the core portfolio, excluding a prior-year one-time milestone, despite traditional first-quarter seasonality. The divestiture is expected to unlock substantial near-term shareholder value while leveraging Apotex's larger market presence to broaden distribution of the legacy brands. Operational momentum continued with the FDA approval of expanded labeling for Caldolor to include postoperative pain management for patients as young as 3 months. The company secured FDA clearance for the Vaprisol manufacturing facility, enabling them to submit for manufacture and, pending approval of that submission, relaunch the brand later in 2026. Management attributes the successful 2025 performance to double-digit sales growth and significant cash flow, which provided the foundation for this strategic pivot. Following the close of the Apotex transaction, Cumberland will no longer target double-digit revenue growth as it shifts focus toward clinical development. Operating expenses are expected to decrease significantly post-closing as Apotex assumes responsibility for sales, marketing, manufacturing, and FDA fees. Clinical spending levels for 2026 are projected to remain stable as the company prioritizes its ifetroban chemical entity across multiple advanced clinical programs. Management expects to announce interim efficacy results for the Fighting Fibrosis trial in idiopathic pulmonary fibrosis later this year. The company is finalizing regulatory pathways for ifetroban in Duchenne muscular dystrophy following a recent FDA Fast Track designation and follow-up meetings. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. The company expects modest income tax impact from the $100 million sale due to a $30 million tax basis in the assets and over $53 million in tax net operating loss carryforwards. A $3 million milestone payment from the prior year's Q1 (related to Vibativ in China) created a difficult year-over-year comparison for total revenue. Cumberland maintains a 30% ownership position in Talicia Holdings, Inc., which is accounted for using the equity method. Management flagged that individual brand shipments fluctuate quarterly based on customer buying patterns and the timing of international orders. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.